journal
https://read.qxmd.com/read/38376607/summary-of-research-what-is-the-true-impact-of-cognitive-impairment-for-people-living-with-multiple-sclerosis-a-commentary-of-symposium-discussions-at-the-2020-european-charcot-foundation
#1
JOURNAL ARTICLE
Sarah A Morrow, Paola Kruger, Dawn Langdon, Nektaria Alexandri
Cognitive symptoms affect disease management and activities of daily living for people living with multiple sclerosis (MS). This summary of research article summarises previously published discussions ('What is the true impact of cognitive impairment for people living with multiple sclerosis? A commentary of symposium discussions at the 2020 European Charcot Foundation') from the 2020 European Charcot Foundation meeting between a patient expert living with MS, a neuropsychologist and a neurologist about the impact of cognitive impairment on people living with MS...
February 20, 2024: Neurology and Therapy
https://read.qxmd.com/read/38367176/monitoring-of-perioperative-microcirculation-dysfunction-by-near-infrared-spectroscopy-for-neurological-deterioration-and-prognosis-of-aneurysmal-subarachnoid-hemorrhage-an-observational-longitudinal-cohort-study
#2
JOURNAL ARTICLE
Shunyan Yang, Binbin Tan, Jie Lin, Xia Wang, Congying Fu, Kaishan Wang, Jinyu Qian, Jin Liu, Jishu Xian, Liang Tan, Hua Feng, Yujie Chen, Lihua Wang
INTRODUCTION: No evidence has established a direct causal relationship between early microcirculation disturbance after aneurysmal subarachnoid hemorrhage (aSAH) and neurological function prognosis, which is the key pathophysiological mechanism of early brain injury (EBI) in patients with aSAH. METHODS: A total of 252 patients with aSAH were enrolled in the Neurosurgical Intensive Care Unit of Southwest Hospital between January 2020 and December 2022 and divided into the no neurological deterioration, early neurological deterioration, and delayed neurological deterioration groups...
February 17, 2024: Neurology and Therapy
https://read.qxmd.com/read/38361080/safety-and-tolerability-of-combining-cgrp-monoclonal-antibodies-with-gepants-in-patients-with-migraine-a-retrospective-study
#3
JOURNAL ARTICLE
Taoufik Alsaadi, Reem Suliman, Vanessa Santos, Ibrahim Al Qaisi, Princess Carmina, Batool Aldaher, Shadi Haddad, Yazan Bader
INTRODUCTION: The introduction of clacitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) has revolutionized the treatment of migraines. In clinical practice gepants might be considered as a valid option to treat acute attacks in patients with migraine who are treated with mAbs. However, the safety and tolerability of such a combination is not well addressed in the real-world setting. We designed this study to evaluate the safety and tolerability of combining CGRP mAbs with gepants in the management of migraines...
February 15, 2024: Neurology and Therapy
https://read.qxmd.com/read/38345742/understanding-the-symptoms-and-impacts-experienced-by-people-with-relapsing-remitting-ms-a-qualitative-investigation-using-semi-structured-interviews
#4
JOURNAL ARTICLE
Amy Barrett, Oyebimpe Olayinka-Amao, Tjalf Ziemssen, Trishna Bharadia, Christian Henke, Paul Kamudoni
INTRODUCTION: Multiple sclerosis (MS) is a disabling disease with unpredictable clinical manifestations. As clinical assessments may not fully capture the impact of MS on quality of life, they can be complemented by patient-reported outcome (PRO) measures to provide a more comprehensive picture of MS disease state and impact. The objectives of this study were to explore the experiences of people with relapsing-remitting MS, including symptoms and impacts on daily life, and to provide a conceptual model of MS outcomes...
February 12, 2024: Neurology and Therapy
https://read.qxmd.com/read/38345741/dyskinesia-and-pain-in-advanced-parkinson-s-disease-post-hoc-analysis-from-the-phase%C3%A2-3b-open-label-randomized-dyscover-study
#5
JOURNAL ARTICLE
Eric Freire-Alvarez, Paola Vanni, Egon Kurča, Lydia Lopez-Manzanares, Norbert Kovács, Cleanthe Spanaki, Tianming Gao, Lars Bergmann, Olga Sánchez-Soliño
INTRODUCTION: The DYSCOVER study was a phase 3b, open-label, randomized trial (NCT02799381) that evaluated levodopa-carbidopa intestinal gel (LCIG) versus optimized medical treatment (OMT) in patients with Parkinson's disease (PD) and a high burden of dyskinesia at baseline (defined as Unified Dyskinesia Rating Scale [UDysRS] total score ≥ 30). At week 12, patients receiving LCIG versus OMT experienced significant improvements in dyskinesia, pain, and health-related outcomes...
February 12, 2024: Neurology and Therapy
https://read.qxmd.com/read/38329615/long-term-effectiveness-of-galcanezumab-in-the-prevention-of-migraine-an-italian-retrospective-analysis-reality
#6
JOURNAL ARTICLE
Fabrizio Vernieri, Luigi Francesco Iannone, Simona Guerzoni, Antonio Russo, Piero Barbanti, Grazia Sances, Sabina Cevoli, Renata Rao, Carlo Lovati, Anna Ambrosini, Carlotta Buzzoni, Federico Battisti, Laura Vatteone, Steffy Martin Luther King, Federico Torelli
BACKGROUND: Galcanezumab is approved in the European Union (EU) as migraine prophylaxis in adults with at least four migraine days per month. The aim of this retrospective observational study was to evaluate the long-term effectiveness of galcanezumab on migraine-related burdens and its impact on the use of healthcare resources for migraine prophylaxis in an Italian setting. METHODS: This retrospective study was conducted in patients with migraine who initiated treatment with galcanezumab for migraine prevention between September 2019 and December 2020...
February 8, 2024: Neurology and Therapy
https://read.qxmd.com/read/38308801/clinical-and-polysomnographic-characteristics-of-adult-patients-with-suspected-obstructive-sleep-apnea-from-different-sleep-clinics-at-a-single-tertiary-center
#7
JOURNAL ARTICLE
Eunmi Lee, Hyunjo Lee
INTRODUCTION: The characteristics of patients across different sleep clinics may vary because they selectively visit specific specialists on the basis of their primary symptoms. This study aimed to compare the clinical and polysomnography (PSG) features of patients with suspected obstructive sleep apnea (OSA) at three sleep specialty clinics (otolaryngology [ENT], neurology [NR], and psychiatry [PSY]). METHODS: We retrospectively analyzed the medical records and PSG reports of adult patients who underwent full-night PSG between January 2022 and June 2023 at a tertiary medical center...
February 3, 2024: Neurology and Therapy
https://read.qxmd.com/read/38300459/conversion-to-brivaracetam-monotherapy-in-clinical-practice-a-retrospective-study
#8
JOURNAL ARTICLE
Simona Lattanzi, Nicoletta Foschi, Chiara Martellino, Daniela Audenino, Giovanni Boero, Paolo Bonanni, Edoardo Ferlazzo, Valentina Chiesa, Filippo Dainese, Marta Piccioli, Alessandra Ferrari, Angelo Labate
INTRODUCTION: The study aimed to evaluate the effectiveness and safety of brivaracetam (BRV) as conversion monotherapy in adults with focal epilepsy treated in the context of real-world clinical practice. METHODS: This was a retrospective, observational, non-interventional study in adults with focal epilepsy who converted to BRV monotherapy following the withdrawal of background antiseizure medications (ASMs). Primary effectiveness outcome was the retention rate of BRV as single ASM at 6 and 12 months...
February 1, 2024: Neurology and Therapy
https://read.qxmd.com/read/38263492/textbook-outcomes-among-patients-with-aneurysmal-subarachnoid-hemorrhage-following-endovascular-treatment
#9
JOURNAL ARTICLE
Zisheng Liu, Yuhao Tan, Yanpeng Wei, Dongwei Dai, Rui Zhao, Qiang Li, Qinghai Huang, Yi Xu, Pengfei Yang, Jun Sun, Jianmin Liu, Qiao Zuo
INTRODUCTION: The case fatality rate among patients with aneurysmal subarachnoid hemorrhage (aSAH) has decreased progressively, with numerous patients subjected to contemporary paradigms that minimize the use of agonizing therapeutic processes. The concept of the "Textbook Outcome" (TO), a composite outcome that highlights numerous favorable outcomes, was developed in the context of gastrointestinal tumor surgeries and expeditiously extended across diverse surgical spheres. The aim of this study was to explore the factors hindering the achievement of optimal prognoses in postinterventional aSAH patients, employ textbook outcomes, and establish predictive models...
January 23, 2024: Neurology and Therapy
https://read.qxmd.com/read/38244179/population-pharmacokinetic-analysis-to-support-and-facilitate-switching-from-risperidone-formulations-to-rykindo-in-patients-with-schizophrenia
#10
JOURNAL ARTICLE
Wenyan Wang, Xiaofeng Wang, Ying Dong, David P Walling, Pinglan Liu, Wanhui Liu, Yanan Shi, Kaoxiang Sun
INTRODUCTION: RYKINDO® (Rykindo) is a novel, long-acting injectable risperidone formulation administered biweekly (Q2W) through intramuscular gluteal injection for the treatment of schizophrenia in adult patients. This analysis was conducted to demonstrate that the clinical outcomes of Rykindo are equivalent to those of RISPERDAL CONSTA® (Consta; Q2W), and to establish a dosing methodology to switch from Consta to Rykindo, as well as to introduce Rykindo to patients who are currently on oral RISPERDAL® (Risperdal)...
January 20, 2024: Neurology and Therapy
https://read.qxmd.com/read/38240944/acute-treatment-of-migraine-expert-consensus-statements-from-the-united-arab-emirates-uae
#11
JOURNAL ARTICLE
Taoufik Alsaadi, Deeb M Kayed, Abubaker Al-Madani, Ali Mohamed Hassan, Derk Krieger, Naji Riachi, Pournamy Sarathchandran, Suhail Al-Rukn
INTRODUCTION: Migraine, characterized by recurrent headaches and often accompanied by other symptoms like nausea, vomiting, and sensitivity to light and sound, significantly impacts patients' quality of life (QoL) and daily functioning. The global burden of migraines is reflected not only in terms of reduced QoL but also in the form of increased healthcare costs and missed work or school days. While UAE (United Arab Emirates)-specific consensus-based recommendations for the effective use of preventive calcitonin gene-related peptide (CGRP)-based migraine therapies have been published previously, an absence of such regional guidance on the management of acute migraine represents a gap that needs to be urgently addressed...
January 19, 2024: Neurology and Therapy
https://read.qxmd.com/read/38236314/eptinezumab-demonstrated-efficacy-regardless-of-prior-preventive-migraine-treatment-failure-type-post-hoc-analyses-of-the-deliver-study
#12
JOURNAL ARTICLE
Patricia Pozo-Rosich, Messoud Ashina, Stewart J Tepper, Sidsel Jensen, Line Pickering Boserup, Mette Krog Josiassen, Bjørn Sperling
INTRODUCTION: In the DELIVER study, eptinezumab reduced monthly migraine days (MMDs) more than placebo in patients with 2-4 prior preventive migraine treatment failures. This post hoc analysis evaluated the efficacy of eptinezumab across the 24-week placebo-controlled period of the DELIVER study in subgroups defined by prior treatment failure type. METHODS: DELIVER (NCT04418765) randomized adults with migraine to eptinezumab 100 mg, 300 mg, or placebo, administered intravenously every 12 weeks...
January 18, 2024: Neurology and Therapy
https://read.qxmd.com/read/38227133/impact-of-istradefylline-on-levodopa-dose-escalation-in-parkinson-s-disease-istra-adjust-pd-study-a-multicenter-open-label-randomized-parallel-group-controlled-study
#13
JOURNAL ARTICLE
Taku Hatano, Renpei Sengoku, Hiroshi Nagayama, Naotake Yanagisawa, Asako Yoritaka, Keisuke Suzuki, Noriko Nishikawa, Yohei Mukai, Kyoichi Nomura, Norihito Yoshida, Morinobu Seki, Miho Kawabe Matsukawa, Hiroo Terashi, Katsuo Kimura, Jun Tashiro, Shigeki Hirano, Hidetomo Murakami, Hideto Joki, Tsuyoshi Uchiyama, Hideki Shimura, Kotaro Ogaki, Jiro Fukae, Yoshio Tsuboi, Kazushi Takahashi, Toshimasa Yamamoto, Kenichi Kaida, Ryoko Ihara, Kazutomi Kanemaru, Osamu Kano
INTRODUCTION: A higher levodopa dose is a risk factor for motor complications in Parkinson's disease (PD). Istradefylline (IST) is used as adjunctive treatment to levodopa in PD patients with off episodes, but its impact on levodopa dose titration remains unclear. The objective of this study was to investigate the effect of IST on levodopa dose escalation in PD patients with wearing-off. METHODS: This was a multicenter, open-label, randomized, parallel-group controlled study (ISTRA ADJUST PD) in which PD patients experiencing wearing-off (n = 114) who were receiving levodopa 300-400 mg/day were randomized to receive IST or no IST (control)...
January 16, 2024: Neurology and Therapy
https://read.qxmd.com/read/38206453/twenty-years-of-subcutaneous-interferon-beta-1a-for-multiple-sclerosis-contemporary-perspectives
#14
REVIEW
Mark S Freedman, Patricia K Coyle, Kerstin Hellwig, Barry Singer, Daniel Wynn, Bianca Weinstock-Guttman, Silva Markovic-Plese, Andrew Galazka, Fernando Dangond, Julie Korich, Anthony T Reder
Multiple sclerosis (MS) is a chronic, progressive, inflammatory disorder of the central nervous system. Relapsing-remitting MS (RRMS), the most common form of the disease, is characterized by transient neurological dysfunction with concurrent accumulation of disability. Over the past three decades, disease-modifying therapies (DMTs) capable of reducing the frequency of relapses and slowing disability worsening have been studied and approved for use in patients with RRMS. The first DMTs were interferon-betas (IFN-βs), which were approved in the 1990s...
January 11, 2024: Neurology and Therapy
https://read.qxmd.com/read/38190001/the-clinical-development-of-taldefgrobep-alfa-an-anti-myostatin-adnectin-for-the-treatment-of-duchenne-muscular-dystrophy
#15
JOURNAL ARTICLE
Francesco Muntoni, Barry J Byrne, Hugh J McMillan, Monique M Ryan, Brenda L Wong, Juergen Dukart, Amita Bansal, Valerie Cosson, Roxana Dreghici, Maitea Guridi, Michael Rabbia, Hannah Staunton, Giridhar S Tirucherai, Karl Yen, Xiling Yuan, Kathryn R Wagner
INTRODUCTION: Duchenne muscular dystrophy (DMD) is a genetic muscle disorder that manifests during early childhood and is ultimately fatal. Recently approved treatments targeting the genetic cause of DMD are limited to specific subpopulations of patients, highlighting the need for therapies with wider applications. Pharmacologic inhibition of myostatin, an endogenous inhibitor of muscle growth produced almost exclusively in skeletal muscle, has been shown to increase muscle mass in several species, including humans...
January 8, 2024: Neurology and Therapy
https://read.qxmd.com/read/38180727/insights-for-healthcare-providers-on-shared-decision-making-in-multiple-sclerosis-a-narrative-review
#16
REVIEW
Sharon Stoll, Kathleen Costello, Scott D Newsome, Hollie Schmidt, Amy B Sullivan, Barry Hendin
Shared decision-making (SDM) between the patient and their healthcare provider (HCP) in developing treatment plans is increasingly recognized as central to improving treatment adherence and, ultimately, patient outcomes. In multiple sclerosis (MS), SDM is particularly crucial for optimizing treatment in a landscape that has grown more complex with the availability of newer, high-efficacy MS therapies. However, little direct evidence on the effectiveness of SDM is available to guide practice. Multiple factors, including patient age, ethnic background, perceptions, invisible MS symptoms, and psychological comorbidities can influence a patient's willingness and ability to participate in SDM...
January 5, 2024: Neurology and Therapy
https://read.qxmd.com/read/38180726/design-and-validation-of-a-clinical-outcome-measure-for-adolescents-and-adult-patients-with-spinal-muscular-atrophy-sma-life-study-protocol
#17
JOURNAL ARTICLE
Pablo Rebollo, Sofía García-López, Mónica Povedano, María G Cattinari, Mercedes Martínez-Moreno, Ángeles Terrancle, Rosana Cabello-Moruno, Juan F Vázquez-Costa
INTRODUCTION: The objective of this study is to develop a clinical tool for the evaluation and follow-up of adolescent and adult patients with 5q spinal muscular atrophy (SMA) and to design its validation. METHODS: This prospective, non-interventional study will be carried out at five centres in Spain and will include patients aged 16 years or older with a confirmed diagnosis of 5q SMA (biallelic mutation of the survival motor neuron 1 [SMN1] gene). A panel of experts made up of neurologists, physiatrists and Spanish patients' association (FundAME), participated in the design of the clinical tool...
January 5, 2024: Neurology and Therapy
https://read.qxmd.com/read/38175489/impact-of-migraine-on-daily-life-results-of-the-observational-survey-of-the-epidemiology-treatment-and-care-of-migraine-overcome-japan-study
#18
JOURNAL ARTICLE
Etsuko Awaki, Takao Takeshima, Yasuhiko Matsumori, Koichi Hirata, Naoki Miyazaki, Ryo Takemura, Satoshi Osaga, Yoshinori Tanizawa, Mika Komori
INTRODUCTION: The impacts of migraine on daily life, including daily activities and fundamental health indicators (sleep and mental health), have not been described in detail for people with migraine in Japan. METHODS: The cross-sectional ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) study was conducted between July and September 2020. Impacts of migraine on housework, family/social/leisure activities, driving, and sleep were assessed using questions from the Migraine Disability Assessment (MIDAS), Migraine-Specific Quality-of-Life Questionnaire, and Impact of Migraine on Partners and Adolescent Children scales and questions developed for OVERCOME (Japan)...
January 4, 2024: Neurology and Therapy
https://read.qxmd.com/read/38175488/rapid-rescue-treatment-with-diazepam-nasal-spray-leads-to-faster-seizure-cluster-termination-in-epilepsy-an-exploratory-post-hoc-cohort-analysis
#19
JOURNAL ARTICLE
Sunita N Misra, Randa Jarrar, John M Stern, Danielle A Becker, Enrique Carrazana, Adrian L Rabinowicz
INTRODUCTION: Although prompt treatment of status epilepticus is standard of care, the effect of timing of rescue therapy administration for seizure clusters in epilepsy remains unknown. Seizure clusters are a rare but clinically important condition, and benzodiazepines are the cornerstone rescue therapy for seizure clusters in epilepsy. We characterized temporal patterns from a large dataset of treated seizure clusters in the safety study of diazepam nasal spray. METHODS: This post hoc analysis used timing data of treated seizure clusters recorded by care partners and patients in seizure diaries during a 1-year safety study...
January 4, 2024: Neurology and Therapy
https://read.qxmd.com/read/38097868/humoral-response-to-sars-cov-2-vaccination-in-patients-with-multiple-sclerosis-and-neuromyelitis-optica-spectrum-disorder-a-real-world-study
#20
JOURNAL ARTICLE
Jorge Millán-Pascual, Gabriel Valero-López, Francisca Iniesta-Martinez, Maria Fuensanta Hellin-Gil, Judith Jimenez-Veiga, Isabel Alejandra López-Tovar, Ana Morales-Ortiz, José E Meca-Lallana
INTRODUCTION: The risk of SARS-CoV-2 infection or severe coronavirus disease 2019 (COVID-19) has been shown to increase in patients with multiple sclerosis (MS). Vaccination is recommended in this patient population, and the effect of disease-modifying treatments (DMTs) on response to vaccination should be considered. METHODS: This prospective, observational, cross-sectional study investigated humoral response after COVID-19 vaccination as well as possible predictors for response in patients with MS and other neuroinflammatory diseases who received DMTs in routine clinical practice in Spain...
December 14, 2023: Neurology and Therapy
journal
journal
49896
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.